259 related articles for article (PubMed ID: 35468048)
1. Adoptive tumor infiltrating lymphocytes cell therapy for cervical cancer.
Zhu Y; Zhou J; Zhu L; Hu W; Liu B; Xie L
Hum Vaccin Immunother; 2022 Nov; 18(5):2060019. PubMed ID: 35468048
[TBL] [Abstract][Full Text] [Related]
2. Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer.
Kumar A; Watkins R; Vilgelm AE
Front Immunol; 2021; 12():690499. PubMed ID: 34140957
[TBL] [Abstract][Full Text] [Related]
3. Tumor-infiltrating lymphocytes for adoptive cell therapy: recent advances, challenges, and future directions.
Granhøj JS; Witness Præst Jensen A; Presti M; Met Ö; Svane IM; Donia M
Expert Opin Biol Ther; 2022 May; 22(5):627-641. PubMed ID: 35414331
[TBL] [Abstract][Full Text] [Related]
4. Adoptive cell therapy using tumor-infiltrating lymphocytes for melanoma refractory to immune-checkpoint inhibitors.
Hirai I; Funakoshi T; Kamijuku H; Fukuda K; Mori M; Sakurai M; Koda Y; Kato J; Mori T; Watanabe N; Noji S; Yaguchi T; Iwata T; Ohta S; Fujita T; Tanosaki R; Handa M; Okamoto S; Amagai M; Kawakami Y
Cancer Sci; 2021 Aug; 112(8):3163-3172. PubMed ID: 34101300
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 expression is associated with tumor infiltrating lymphocytes that predict response to NACT in squamous cell cervical cancer.
D'Alessandris N; Palaia I; Pernazza A; Tomao F; Di Pinto A; Musacchio L; Leopizzi M; Di Maio V; Pecorella I; Benedetti Panici P; Della Rocca C
Virchows Arch; 2021 Mar; 478(3):517-525. PubMed ID: 32915266
[TBL] [Abstract][Full Text] [Related]
6. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma.
Dudley ME; Gross CA; Somerville RP; Hong Y; Schaub NP; Rosati SF; White DE; Nathan D; Restifo NP; Steinberg SM; Wunderlich JR; Kammula US; Sherry RM; Yang JC; Phan GQ; Hughes MS; Laurencot CM; Rosenberg SA
J Clin Oncol; 2013 Jun; 31(17):2152-9. PubMed ID: 23650429
[TBL] [Abstract][Full Text] [Related]
7. Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types.
Kverneland AH; Chamberlain CA; Borch TH; Nielsen M; Mørk SK; Kjeldsen JW; Lorentzen CL; Jørgensen LP; Riis LB; Yde CW; Met Ö; Donia M; Svane IM
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34607899
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of adjuvant immunotherapy with autologous tumor-infiltrating lymphocytes in locally advanced cervical cancer.
Huang H; Nie CP; Liu XF; Song B; Yue JH; Xu JX; He J; Li K; Feng YL; Wan T; Zheng M; Zhang YN; Ye WJ; Li JD; Li YF; Li JY; Cao XP; Liu ZM; Zhang XS; Liu Q; Zhang X; Liu JH; Li J
J Clin Invest; 2022 Aug; 132(15):. PubMed ID: 35727633
[TBL] [Abstract][Full Text] [Related]
9. Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix.
Santin AD; Bellone S; Palmieri M; Bossini B; Roman JJ; Cannon MJ; Bignotti E; Canè S; Pecorelli S
Gynecol Oncol; 2003 May; 89(2):271-80. PubMed ID: 12713991
[TBL] [Abstract][Full Text] [Related]
10. Targeting tumor microenvironment using tumor-infiltrating lymphocytes as therapeutics against tumorigenesis.
Qayoom H; Sofi S; Mir MA
Immunol Res; 2023 Aug; 71(4):588-599. PubMed ID: 37004645
[TBL] [Abstract][Full Text] [Related]
11. Coupling programmed cell death 1-positive tumor-infiltrating T cells with anti-programmed cell death 1 antibody improves the efficacy of adoptive T-cell therapy.
Chu J; Wang C; Ma Q; Dai H; Xu J; Ogunnaike EA; Peng F; Shi X; Wang C
Cytotherapy; 2022 Mar; 24(3):291-301. PubMed ID: 34690063
[TBL] [Abstract][Full Text] [Related]
12. Adherent cell depletion promotes the expansion of renal cell carcinoma infiltrating T cells with optimal characteristics for adoptive transfer.
Braun MW; Abdelhakim H; Li M; Hyter S; Pessetto Z; Koestler DC; Pathak HB; Dunavin N; Godwin AK
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037114
[TBL] [Abstract][Full Text] [Related]
13. Eradicating tumor in a recurrent cervical cancer patient with autologous tumor-infiltrating lymphocytes and a modified lymphodepleting regimen.
Guo J; Luo N; Ai G; Yang W; Zhu J; Li C; Chen R; Zhang C; Liu S; Jin H; Cheng Z
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35177415
[TBL] [Abstract][Full Text] [Related]
14. Tumor-Infiltrating Lymphocytes: Clinical Experience.
Besser MJ; Shapira-Frommer R; Schachter J
Cancer J; 2015; 21(6):465-9. PubMed ID: 26588677
[TBL] [Abstract][Full Text] [Related]
15. Minimally invasive liver resection to obtain tumor-infiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma.
Alvarez-Downing MM; Inchauste SM; Dudley ME; White DE; Wunderlich JR; Rosenberg SA; Kammula US
World J Surg Oncol; 2012 Jun; 10():113. PubMed ID: 22726267
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic analysis of tumor-infiltrating lymphocytes from non-small cell lung cancer and their potential application for adoptive cell therapy.
Ma Y; Ou J; Lin T; Chen L; Wang J; Qiao D; Lai S; Duan C; Cheng Y; Chang R; Zhang C; Wang M
Immunopharmacol Immunotoxicol; 2020 Aug; 42(4):319-329. PubMed ID: 32419542
[TBL] [Abstract][Full Text] [Related]
17. Tumor-infiltrating lymphocytes predict survival outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy.
Ohno A; Iwata T; Katoh Y; Taniguchi S; Tanaka K; Nishio H; Nakamura M; Morisada T; Chen G; Saito M; Yaguchi T; Kawakami Y; Aoki D
Gynecol Oncol; 2020 Nov; 159(2):329-334. PubMed ID: 32829964
[TBL] [Abstract][Full Text] [Related]
18. LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes generate tumor specific T cells in patients with metastatic soft tissue sarcoma.
Nielsen M; Monberg T; Sundvold V; Albieri B; Hovgaard D; Petersen MM; Krarup-Hansen A; Met Ö; Camilio K; Clancy T; Stratford R; Sveinbjornsson B; Rekdal Ø; Junker N; Svane IM
Oncoimmunology; 2024; 13(1):2290900. PubMed ID: 38125722
[TBL] [Abstract][Full Text] [Related]
19. Adoptive cell therapy in gynecologic cancers: A systematic review and meta-analysis.
Son J; George GC; Nardo M; Krause KJ; Jazaeri AA; Biter AB; Hong DS
Gynecol Oncol; 2022 Jun; 165(3):664-670. PubMed ID: 35400527
[TBL] [Abstract][Full Text] [Related]
20. A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma.
Jiang SS; Tang Y; Zhang YJ; Weng DS; Zhou ZG; Pan K; Pan QZ; Wang QJ; Liu Q; He J; Zhao JJ; Li J; Chen MS; Chang AE; Li Q; Xia JC
Oncotarget; 2015 Dec; 6(38):41339-49. PubMed ID: 26515587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
